Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market 2026 - Players, Regions, Product Types, Application & Forecast Analysis

Chapter 1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview

1.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Definition

1.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Status and Outlook (2019-2032)

1.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Comparison by Region (2019-2032)

1.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Comparison by Type (2019-2032)

1.5 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Comparison by Application (2019-2032)

1.6 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Comparison by Sales Channel (2019-2032)

1.7 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Dynamics

1.7.1 Market Drivers/Opportunities

1.7.2 Market Challenges/Risks

1.7.3 Market News (Products Launch, Mergers, Acquisitions, Expansion, Agreement and Collaborations, Partnerships)

1.7.4 COVID-19 Impacts

1.7.5 Russia-Ukraine War Impacts

1.7.6 US-Israel-Iran War Impacts

Chapter 2 Executive Summary

2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Snapshot

2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Volume & Revenue (2019-2025)

2.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Differential Growth Potential Analysis by Type, (2019-2032) (USD Million)

2.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Differential Growth Potential Analysis by Application, (2019-2032) (USD Million)

2.5 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Differential Growth Potential Analysis by Sales Channels, (2019-2032) (USD Million)

2.6 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Differential Growth Potential Analysis by Region, (2019-2032) (USD Million)

Chapter 3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Segment Analysis by Player

3.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales and Market Share by Player (2023-2025)

3.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Market Share by Player (2023-2025)

3.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Average Price by Player (2023-2025)

3.4 Players Competition Situation & Trends (2023-2025)

3.5 Conclusion of Segment by Player

Chapter 4 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Segment Analysis by Type

4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Type

4.1.1 EXONDYS

4.1.2 Emflaza

4.1.3 Translarna

4.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales and Market Share by Type (2019-2025)

4.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Market Share by Type (2019-2025)

4.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Average Price by Type (2019-2025)

4.5 Leading Players of Duchenne Muscular Dystrophy (DMD) Therapeutics by Type in 2025

4.6 Conclusion of Segment by Type

Chapter 5 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Segment Analysis by Application

5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Application

5.1.1 Hospitals

5.1.2 Clinics

5.1.3 Home Care

5.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Market Share by Application (2019-2025)

5.3 Leading Consumers of Duchenne Muscular Dystrophy (DMD) Therapeutics by Application in 2025

5.4 Conclusion of Segment by Application

Chapter 6 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Segment Analysis by Sales Channel

6.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Sales Channel

6.1.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, by Direct Channel Market Analysis (2019-2032) (USD Million)

6.1.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, by Distribution Channel Market Analysis (2019-2032) (USD Million)

6.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Market Share by Sales Channel (2019-2025)

6.3 Leading Distributors/Dealers of Duchenne Muscular Dystrophy (DMD) Therapeutics by Sales Channel in 2025

6.4 Conclusion of Segment by Sales Channel

Chapter 7 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Segment Analysis by Region

7.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and CAGR by Region (2019-2032)

7.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales and Market Share by Region (2019-2025)

7.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Market Share by Region (2019-2025)

7.4 North America

7.4.1 North America Market by Country

7.4.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type

7.4.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application

7.4.4 United States

7.4.5 Canada

7.4.6 Mexico

7.5 Europe

7.5.1 Europe Market by Country

7.5.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type

7.5.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application

7.5.4 Germany

7.5.5 United Kingdom

7.5.6 France

7.5.7 Italy

7.5.8 Russia

7.5.9 Spain

7.5.10 Benelux

7.5.11 Poland

7.5.12 Austria

7.5.13 Portugal

7.5.14 Rest of Europe

7.6 Asia-Pacific

7.6.1 Asia-Pacific Market by Country

7.6.2 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type

7.6.3 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application

7.6.4 China

7.6.5 Japan

7.6.6 Korea

7.6.7 India

7.6.8 Southeast Asia

7.6.9 Australia

7.6.10 Taiwan

7.6.11 Rest of Asia Pacific

7.7 South America

7.7.1 South America Market by Country

7.7.2 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type

7.7.3 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application

7.7.4 Brazil

7.7.5 Argentina

7.7.6 Colombia

7.7.7 Chile

7.7.8 Peru

7.7.9 Venezuela

7.7.10 Rest of South America

7.8 Middle East & Africa

7.8.1 Middle East & Africa Market by Country

7.8.2 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type

7.8.3 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application

7.8.4 UAE

7.8.5 Saudi Arabia

7.8.6 South Africa

7.8.7 Egypt

7.8.8 Nigeria

7.9.9 Rest of Middle East & Africa

7.9 Conclusion of Segment by Region

Chapter 8 Profile of Leading Duchenne Muscular Dystrophy (DMD) Therapeutics Players

8.1 Sarepta Therapeutics

8.1.1 Company Snapshot

8.1.2 Product/Service Offered

8.1.3 Business Performance (Sales, Price, Revenue, Gross Margin and Market Share)

8.1.4 Recent Developments

8.2 PTC Therapeutics

8.2.1 Company Snapshot

8.2.2 Product/Service Offered

8.2.3 Business Performance (Sales, Price, Revenue, Gross Margin and Market Share)

8.2.4 Recent Developments

8.3 Pfizer

8.3.1 Company Snapshot

8.3.2 Product/Service Offered

8.3.3 Business Performance (Sales, Price, Revenue, Gross Margin and Market Share)

8.3.4 Recent Developments

8.4 Bristol-Myers Squibb

8.4.1 Company Snapshot

8.4.2 Product/Service Offered

8.4.3 Business Performance (Sales, Price, Revenue, Gross Margin and Market Share)

8.4.4 Recent Developments

8.5 Italfarmaco

8.5.1 Company Snapshot

8.5.2 Product/Service Offered

8.5.3 Business Performance (Sales, Price, Revenue, Gross Margin and Market Share)

8.5.4 Recent Developments

8.6 Santhera Pharmaceuticals

8.6.1 Company Snapshot

8.6.2 Product/Service Offered

8.6.3 Business Performance (Sales, Price, Revenue, Gross Margin and Market Share)

8.6.4 Recent Developments

8.7 ...

8.7.1 Company Snapshot

8.7.2 Product/Service Offered

8.7.3 Business Performance (Sales, Price, Revenue, Gross Margin and Market Share)

8.7.4 Recent Developments

Chapter 9 Upstream and Downstream Analysis of Duchenne Muscular Dystrophy (DMD) Therapeutics

9.1 Industrial Chain of Duchenne Muscular Dystrophy (DMD) Therapeutics

9.2 Upstream of Duchenne Muscular Dystrophy (DMD) Therapeutics

9.2.1 Raw Materials (If Applicable)

9.2.2 Manufacturing Cost Structure (If Applicable)

9.2.3 Manufacturing Process (If Applicable)

9.3 Downstream of Duchenne Muscular Dystrophy (DMD) Therapeutics

9.3.1 Leading Distributors/Dealers of Duchenne Muscular Dystrophy (DMD) Therapeutics

9.3.2 Leading Consumers of Duchenne Muscular Dystrophy (DMD) Therapeutics

Chapter 10. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Industry Analysis

10.1. Porter's Five Forces Analysis

10.1.1. Threat of New Entrants

10.1.2. Bargaining Power of Buyers/Consumers

10.1.3. Bargaining Power of Suppliers

10.1.4. Threat of Substitute Types

10.1.5. Intensity of Competitive Rivalry

10.2. Major Growth Avenues within Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market

10.2.1. Product Types

10.2.2. Applications

10.2.3. Sales Channels

10.2.4. Country

10.3. Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Ecosystem

10.4. Price Trend Analysis (If Applicable)

10.5. Buying Criteria (If Applicable)

10.6. Regulations (If Applicable)

Chapter 11 Development Trend of Duchenne Muscular Dystrophy (DMD) Therapeutics (2026-2032)

11.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (Sales and Revenue) Forecast (2026-2032)

11.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and CAGR Forecast by Region (2026-2032)

11.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and CAGR Forecast by Type (2026-2032)

11.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and CAGR Forecast by Application (2026-2032)

11.5 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and CAGR Forecast by Sales Channel (2026-2032)

Chapter 12. Import - Export Analysis (If Applicable)

12.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Import-Export (2019-2025)

12.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Import-Export (2019-2025)

12.3 Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Import-Export (2019-2025)

12.4 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Import-Export (2019-2025)

12.5 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Import-Export (2019-2025)

Chapter 13. Demand-Supply Gap Analysis

13.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Demand-Supply (2019-2025)

13.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Demand-Supply (2019-2025)

13.3 Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Demand-Supply (2019-2025)

13.4 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Demand-Supply (2019-2025)

13.5 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Demand-Supply (2019-2025)

Chapter 14 Appendix

14.1 Research Methodology

14.2 Data Sources